Cureus
October 1, 2022
Dev B Goel, Sarju Zilate
24 citations
Psilocybin is a plant alkaloid that is derived from precursors of tryptamine and is present in many different types of mushrooms. It has been utilized by indigenous peoples of Central and South America for centuries in a ceremonial setting to promote spiritual experiences. Indigenous societies have long employed psilocybin and other 5-HT 2A agonist classic psychedelics in their rites. They were...
International Journal of Molecular Sciences
September 28, 2022
Dominika Psiuk, Emilia Magdalena Nowak, Natalia Dycha et al.
36 citations
This publication discusses two compounds belonging to the psychoactive substances group which are studied in the context of depression treatment—psilocybin and esketamine. The former is a naturally occurring psychedelic. The latter was invented in the laboratory exactly 60 years ago. Although the substances were controversial in the past, recent studies indicate the potential of those...
Research Square
September 20, 2022
Jakub Vohryzek, Joana Cabral, Louis-David Lord et al.
10 citations
preprint
Abstract Psilocybin therapy for depression has started to show promise, yet the underlying causal mechanisms are not currently known. Here we leveraged the differential outcome in responders and non-responders to psilocybin (10mg and 25mg, 7 days apart) therapy for depression - to gain new insights into regions and networks implicated in the restoration of healthy brain dynamics. We used...
Letters in Applied NanoBioScience
September 17, 2022
3 citations
Medical hallucinogens have been important compounds of research interest in recent years. Computational chemistry methods like Density Functional Theory (DFT) calculations at BP86/Def2-TZVP level are carried out to get more insight into the structural preferences and mechanism of hallucinogens like psilocybin and mescaline derivatives at the molecular level. The molecular structure, reactivity,...
Consciousness, Spirituality & Transpersonal Psychology
September 12, 2022
Kavita Golia
1 citation
This phenomenological research explored the fast-growing societal trend in psilocybin microdosing, whereby a sub-perceptual amount of the psychedelic is consumed regularly. Anecdotal reports of microdosing have suggested that individuals can experience the relief of depressive symptoms, greater creativity and focus, deeper connections, and improvements in several mental health issues. Research...
medRxiv
September 9, 2022
Devon Stoliker, Leonardo Novelli, Franz X. Vollenweider et al.
4 citations
preprint
Abstract Classic psychedelics alter sense of self and patterns of self-related thought. These changes are hypothesised to underlie their therapeutic efficacy across internalising pathologies such as addiction and depression. Using resting-state functional MRI images from a randomised, double blinded, placebo-controlled clinical trial of 24 healthy adults under 0.215mg/kg psilocybin, we...
Læknablaðið
September 6, 2022
Arny Johannesdottir, Engilbert Sigurðsson
4 citations
The hallucinogen psilocybin is a potential novel treatment for treatment-resistant depression (TRD). Our goal is to review current knowledge on psilocybin and its efficacy in TRD. Literature searches were done on PubMed, Web of Science and Google Scholar, references reviewed in identified articles and other articles found on the website of COMPASS Pathways. Psilocybin treatment consists usually...
Pain
September 5, 2022
Matthew Lyes, Joel Castellanos, Timothy Furnish et al.
55 citations
Abstract Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are few published clinical trials of...
Psychopharmacology
September 1, 2022
Camila Sanz, Federico Cavanna, Stephanie Müller et al.
1 citation
Serotonergic psychedelics are being studied as novel treatments for mental health disorders and as facilitators of improved well-being, mental function, and creativity. Recent studies have found mixed results concerning the effects of low doses of psychedelics ("microdosing") on these domains. However, microdosing is generally investigated using instruments designed to assess larger doses of...
BJPsych Open
September 1, 2022
Tommaso Barba, Sarah Buehler, Hannes Kettner et al.
57 citations
Background Major depressive disorder is often associated with maladaptive coping strategies, including rumination and thought suppression. Aims To assess the comparative effect of the selective serotonin reuptake inhibitor escitalopram, and the serotonergic psychedelic psilocybin (COMP360), on rumination and thought suppression in major depressive disorder. Method Based on data derived from a...